WO2004004786A1 - Scanning suspension comprising a particle with a diameter of at least 1 micrometer - Google Patents
Scanning suspension comprising a particle with a diameter of at least 1 micrometer Download PDFInfo
- Publication number
- WO2004004786A1 WO2004004786A1 PCT/NL2003/000485 NL0300485W WO2004004786A1 WO 2004004786 A1 WO2004004786 A1 WO 2004004786A1 NL 0300485 W NL0300485 W NL 0300485W WO 2004004786 A1 WO2004004786 A1 WO 2004004786A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- particle
- scanning
- tumour
- suspension
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1255—Granulates, agglomerates, microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to the field of medicine. More specifically, the invention relates to the field of diagnostics and radiotherapy.
- disorders which display a significant 5 different pattern in each individual patient involve the need for very careful and accurate diagnosis.
- disorders for instance comprise tumour-related diseases. If a patient has been found to suffer from a tumour, it is important to obtain reliable insight into the status of the disease. For instance the growth and position of the tumour should be established, and it should be determined
- MRI magnetic resonance imaging
- a contrast agent is often used in order to be capable of obtaining a scanning image.
- ferrite particles and gadolinium-DTPA (diethylaminetriaminepentaacetic acid) complexes are often used in contrast agents for MR scanning. This way, a good impression can be obtained of internal disorders, like the presence of (a) tumour(s).
- a treatment is often started involving administration of a pharmaceutical composition to a patient. It is often important to monitor the status of a patient during treatment as well. For instance the course of a treatment and targeting of a drug can be monitored, as well as possible side effects which may imply a need for terminating, or temporarily interrupting, a
- tumour growth can sometimes be counteracted by internal radiotherapy comprising administration of radioactive particles to an individual. If said radioactive particles accumulate inside and/or around the tumour, specific local treatment is possible.
- radioactive particles accumulate inside and/or around the tumour.
- specific local treatment is possible.
- the exact distribution of the radioactive particles is determined by firstly administering a tracer dose comprising said radioactive particles. This involves extra exposure of radioactivity, both for the patient and the medical staff, which is unwanted.
- radioactive particles such as radioactive yttrium
- radioactive yttrium particles can hardly be detected with a gamma camera.
- other radioactive particles for example: technetium labelled albumin particles
- technetium labelled albumin particles which can be detected with a gamma camera and which are expected to target and distribute approximately similar as said yttrium particles are administered before treatment.
- a distribution of said other radioactive particles is then determined. Because said distribution of said other radioactive particles is considered to be approximately similar to a distribution of yttrium, it can approximately be estimated whether significant shunting of yttrium to the gastroduodenum and/or the lungs will occur.
- a scanning suspension of the invention can be used for existing applications. New applications with a suspension of the invention are also herewith provided.
- the invention provides a scanning suspension comprising a particle which is capable of at least in part disturbing a magnetic field, wherein said particle comprises a diameter of at least 1 ⁇ m. Said particle can be detected by a non-radioactive scanning method such as MRI.
- said scanning suspension comprises an MRI scanning suspension. More preferably, said particle comprises holmium.
- a use of a particle which is capable of at least in part disturbing a magnetic field for the preparation of a scanning suspension, wherein said particle comprises a diameter of at least 1 ⁇ m is also herewith provided.
- Methods to generate a scanning suspension such as an MRI scanning suspension, are known in the art and need no further description here.
- a scanning suspension of the invention With a scanning suspension of the invention a scanning image can be obtained.
- the invention provides a use of a scanning suspension comprising a particle which is capable of at least in part disturbing a magnetic field for obtaining a scanning image, wherein said particle comprises a diameter of at least 1 ⁇ m.
- said scanning image comprises an MR scanning image.
- the meaning of the word suspension has to be understood as at least including dispersions.
- a scanning suspension of the invention is suitable for determining a flowing behaviour of a particle. Since a scanning suspension of the invention comprises a particle of at least 1 ⁇ m, it can simulate the flowing pattern of such relatively large particles. A use of a scanning suspension comprising a particle with a diameter of at least 1 ⁇ m which is capable of at least in part disturbing a magnetic field for determining the flowing behaviour of said particle is therefore also herewith provided. A scanning suspension of the invention, comprising a particle with a diameter of at least 1 ⁇ m which is capable of at least in part disturbing a magnetic field, is also very suitable for detecting a site of angiogenesis. A site of angiogenesis can be detected by determining the flowing behaviour of said particle. Preferably said particle comprises holmium.
- the size of said particle can be chosen such to enable said particle to get stuck in a blood vessel.
- said size comprises a diameter of about 3-5 ⁇ m.
- a site of angiogenesis can be detected after administration of said particles to an individual. At a site with many (developing) blood vessels, the concentration of stuck particles will be high compared to other parts of the body. Detection of said site is thus possible, for instance by MRI scanning.
- One embodiment of the invention therefore provides a use of the invention for detecting a site of angiogenesis.
- a scanning suspension of the invention is also very suitable for detecting a tumour. This can for instance be performed by determining the flowing behaviour of a particle of the invention, and/or by detecting a site of angiogenesis, with a use according to the invention.
- a presence of a tumour often involves a site of angiogenesis, because a tumour often needs much oxygen and nutrients for a high metabolism rate. Therefore new blood vessels are generated around said tumour.
- a site of angiogenesis can be indicative for a presence of a tumour.
- Said tumour can be detected without the need of using radioactive material. Alternatively, particles with low radioactivity can be used. After a tumour has been detected, said tumour can be treated with a therapeutic composition comprising the same kind of particles as said scanning suspension.
- said particles are preferably rendered (more) radioactive.
- the particles of said diagnostic composition and the particles of said therapeutic composition are chemically the same. Therefore, the distribution of the radioactive particles of said therapeutic composition can be adequately predicted by determining the distribution of the particles of a scanning suspension of the invention.
- the size of the particles are preferably sufficiently large to avoid an equal distribution throughout the whole body.
- said therapeutic composition comprises a particle of the invention which is provided with at least one therapeutically active compound, for instance capable of treating a tumour.
- the invention therefore provides a use of the invention for detecting a tumour.
- said tumour comprises a liver metastasis.
- a use of the invention is provided wherein said scanning suspension comprises an MRI scanning suspension.
- a use of the invention wherein said particle comprises a diameter sufficiently large to enable said particle to be stuck within a tumour.
- Such particle is very suitable for detecting a tumour. More preferably, said particle is at least in part capable of flowing through non-tumorous vessels. Such particle can stick in a tumour vessel while less sticking in normal vessels. This is possible because of the fact that tumour vessels are mostly somewhat smaller and more irregularly formed than normal vessels. This way, tumour tissue can be very adequately distinguished from normal tissue, because a higher concentration of particles of the invention will be present in tumour tissue.
- Said particle of the invention preferably comprises a diameter of approximately 1-10 ⁇ m. More preferably, such particle comprises a diameter of about 2-8 ⁇ m, most preferably about 3-5 ⁇ m.
- a scanning suspension of the invention comprising particles, which are capable of at least in part disturbing a magnetic field, with a small diameter, for instance about 3 ⁇ m. Then it can be determined whether those particles stick within tumorous vessels. If they do not stick within said tumorous vessels yet (the size of tumorous vessels will vary to some extent) one can administer a second dose of scanning suspension comprising particles of the invention with a somewhat larger diameter, for instance about 4 ⁇ m. If these particles still do not stick within said tumorous vessels, a scanning suspension comprising particles of the invention with an even larger diameter can be administered, etc.
- the minimal diameter can be determined allowing a particle of the invention to stick within a certain tumour while still being capable of flowing through non-tumorous vessels.
- Said minimal diameter can vary between different tumours, and between different patients. Said minimal diameter is often between 3-5 ⁇ m. This way it is possible to detect a tumour with a scanning suspension of the invention comprising particles of the invention which stick within tumorous vessels while still being capable of flowing through non-tumorous vessels.
- the invention provides a method for detecting a tumour, comprising
- a scanning suspension comprising a particle which is capable of at least in part disturbing a magnetic field, wherein said particle comprises a diameter of at least 1 ⁇ m; - obtaining a scanning image;
- a method of the invention can comprise administering to an individual different scanning suspensions, comprising particles of the invention with different size.
- each different scanning suspension is administered separately, with a time interval between administration of each suspension.
- different scanning suspensions can be administered simultaneously, or shortly after one another.
- a particle of the invention comprises a diameter of approximately 15-200 ⁇ m, more specifically 15-100 ⁇ m, even more specifically 20-100 ⁇ m, more preferably 20 to 50 or 80-100 ⁇ m.
- a particle of this size is very suitable for radiotherapeutic purposes.
- Said particle comprises a diameter sufficiently large to enable said particle to be lodged within arterioles.
- said particle is suitable for embohzing a blood vessel, preferably embohzing an arteriole.
- a tumour can be deprived from blood, and therefore be deprived from oxygen and nutrients, by lodging at least one blood vessel near said tumour with a particle of the invention. This is possible because of the fact that a tumour receives an increased blood flow as compared to normal tissue.
- an increased amount of particles of the invention will lodge in and around a tumour as compared to normal tissue.
- tumours in the liver receive their blood for the greater part from the hepatic artery while normal liver tissue receives its blood mainly from the portal vein.
- Said particles can for instance be administrated to the hepatic artery with a catheter.
- Embohzing a blood vessel with a particle of the invention is also particularly suitable for treating a tumour present in the throat and/or head of an individual.
- the invention thus provides a use of a particle which is capable of at least in part disturbing a magnetic field, wherein said particle comprises a diameter of approximately 20-100 ⁇ m, for embohzing a blood vessel.
- a particle which is capable of at least in part disturbing a magnetic field, wherein said particle comprises a diameter of approximately 20-100 ⁇ m, for embohzing a blood vessel.
- embolisation of tumours for example bone cancer and tumours due to Tuber Sclerosis
- embolisation of tumours for example bone cancer and tumours due to Tuber Sclerosis
- embolisation of the vessels leading to said tumour may lead to retardation of tumour growth and prevent excessive exposure to radiation for patients and staff.
- a particle of the invention is administered to a particle or complex of interest.
- said particle or complex of interest comprises a particle or complex with a desired function which it can perform within an organism.
- said particle or complex of interest comprises an organelle or cell of an organism.
- said particle or complex of interest comprises a liposome or a white blood cell.
- a scanning method such as MRI. This way a presence and/or migration of said particle or complex of interest can be detected.
- a liposome is useful for delivering a nucleic acid of interest to a suitable site for gene therapy.
- liposome has been provided with a particle of the invention it can be determined where said liposome is present inside an organism. It can then be estimated whether a nucleic acid of interest is delivered to a desired site.
- a nucleic acid of interest is delivered to a desired site.
- migration of said white blood cell to a site of inflammation, or to a tumour can be detected using a scanning method such as MRI.
- the invention thus provides a use of a particle of the invention for detecting a presence and/or migration of a particle or complex of interest.
- a suspension comprising a particle which is capable of at least in part disturbing a magnetic field, wherein said particle comprises a diameter of at least 1 ⁇ m is used for the preparation of a kit of parts.
- Said suspension can be used as such as a diagnostic composition.
- said suspension can be used for the preparation of a diagnostic composition.
- Preferably said suspension is essentially non-radioactive.
- Another aliquot of said suspension can be made (more) radioactive. Said other aliquot is very useful for radiotherapy.
- Such radioactive suspension of the invention can thus be used as a therapeutic composition.
- a composition comprising such radioactive suspension of the invention can be used as a therapeutic composition.
- a radioactive therapeutic composition of the invention comprises a particle of the invention which is provided with at least one therapeutically active compound, for instance capable of treating a tumour.
- Said therapeutic composition is for instance capable of treating a tumour simultaneously by radiotherapy and with a therapeutic action of said compound.
- a non-radioactive therapeutic composition of the invention comprises a particle of the invention which is provided with at least one therapeutically active compound, for instance capable of treating a tumour.
- Said therapeutic composition is capable of treating a tumour by a therapeutic action of said compound.
- a particle of the invention can be provided with any therapeutic compound. Such particle is suitable for treatment of any disease against which said therapeutic compound can perform its therapeutic action.
- Said diagnostic composition and said therapeutic composition are suitable for the preparation of a kit of parts. A use of a particle of the invention for the preparation of a kit of parts is therefore also herewith provided.
- the invention provides a kit of parts comprising a diagnostic composition and a therapeutic composition, said diagnostic composition and said therapeutic composition comprising particles of the invention with essentially the same chemical structure, said therapeutic composition being more radioactive than said diagnostic composition.
- said diagnostic composition is essentially non-radioactive.
- said particles comprise holmium.
- Said diagnostic composition can be used to determine a distribution of said particles inside an individual. This can for instance be determined by MRI. Hence, there is now no more need for a radioactive tracer dose. This is both beneficial for the patient and for the medical staff. No special precautionary measures have to be taken against (too much) exposure to radioactive radiation.
- a distribution pattern has to be determined within limited time, before radioactivity has decayed.
- a diagnostic composition of the invention is essentially non-radioactive, a distribution pattern of said particles does not have to be determined within limited time. Said distribution can now be determined during the whole time that said particles are present within an individual. Hence, more time is available now for determining a distribution pattern.
- the optimal amount of radioactive therapeutic composition to be administered to said individual can be determined, by interpretation of the obtained distribution pattern of said diagnostic composition. It can be determined how many particles accumulate in a tumour, if they are distributed inside said tumour, etc. Because said (more radioactive) particles of said therapeutic composition are chemically the same as said particles of said diagnostic composition, the distribution of said therapeutic composition will be the same as the distribution of said diagnostic composition in said individual.
- a therapeutic composition of the invention comprising a radioactive particle of the invention.
- Said particle of the invention can be directly generated using a radioactive component, such as radioactive holmium.
- a non- radioactive particle of the invention is firstly generated, followed by irradiation of said particle. This avoids the use of high doses of radioactive components, the need for specially equipped (expensive) facilities, etcetera. For instance, after a scanning image has been obtained with a diagnostic composition of the invention, the optimal dosage of a particle of the invention for radiotherapy can be estimated. Such dose of non-radioactive particles of the invention can be provided. Said particles can subsequently be irradiated.
- the present inventors used the high neutron flux facilities in Petten, The Netherlands. Irradiation (neutron flux 5xl0 13 cm -2 .s 1 ) took place for at least 0.5 hour, preferably about 1 hour. Of course, other facilities and other irradiation times can be used as well, provided that the particles of the invention essentially maintain their structure during irradiation. With the term “essentially maintaining their structure” is meant herein that said particles maintain at least 50 %, more preferably 75 %, more preferably 90 %, most preferably 95 % of their content, shape, and or density.
- a scanning suspension of the invention wherein said particle comprises a composition capable of essentially maintaining its structure during irradiation for at least 0.5 hour with a neutron flux of 5xl0 13 cm- 2 .s- 1 . More preferably, said composition is capable of essentially maintaining its structure during irradiation for about 0.5-2 hours with a neutron flux of 5xl0 13 cm- 2 .s- 1 . Most preferably, said composition is capable of essentially maintaining its structure during irradiation for about 1 hour with a neutron flux of 5xl0 13 cm- 2 .s -1 .
- said composition essentially does not comprise water, either bound and/or unbound, since the presence of water has appeared to have a destructive effect during irradiation.
- said particle is biodegradable, allowing for degradation in an animal body after it has been used, for instance for MRI and/or (radio)therapy.
- a kit of parts wherein said diagnostic composition comprises a suspension of the invention.
- a kit of parts comprising a diagnostic composition and a therapeutic composition, said diagnostic composition and said therapeutic composition comprising particles with essentially the same chemical structure which are capable of at least in part disturbing a magnetic field, wherein said particles comprise a diameter of at least 1 ⁇ m, wherein said therapeutic composition comprises a particle of the invention which is provided with at least one therapeutically active compound.
- the distribution of said therapeutic composition can be followed over time using a scanning method such as MRI.
- said therapeutic composition is essentially non-radioactive.
- a particle of the invention comprises a microsphere.
- said microsphere comprises holmium.
- said particle comprises poly(L)-lactic acid.
- poly(L)-lactic acid microspheres are capable of essentially maintaining their structure during irradiation for at least about 1 hour with a neutron flux of 5xl0 13 cm- 2 .s _1 .
- a particle of the invention comprising holmium preferably releases less than 10%, more preferably less than 5%, most preferably less than 1% holmium after and/or during irradiation, because released holmium results in a scanning image that may not be completely indicative for the distribution of said particles of the invention.
- a scanning suspension of the invention wherein said composition comprises holmium chemically bound to a compound capable of essentially maintaining its structure during irradiation for 1 hour with a neutron flux of 5xl0 13 c ⁇ r 2 .s -1 .
- Chemical linkage of holmium is favourable for at least in part avoiding holmium release.
- Irradiated holmium- loaded poly-(L) -lactic acid microspheres are capable of retaining >99.3% of 166 Ho activity after incubation for 288 h, 37°C, in PBS and pig liver homogenate [14].
- Holmium is chemically linked to said microspheres [34].
- a particle of the invention, a scanning suspension of the invention, and/or a kit of parts of the invention therefore preferably comprises said microspheres.
- biodegradable poly (L-lactic acid) microspheres (PLLA-MS) were manufactured in a glass beaker with four baffles, Holmiumacetylacetonate (Ho-AcAc) complex (10 g) and PLLA (6 g) were added to continuously stirred 186 g chloroform.
- Ho-AcAc Holmiumacetylacetonate
- PVA 20 gram was dissolved in 1000 gram continuously stirred water of 40°C and poured into the glass beaker after cooling. The solutions and the beaker were kept at 25°C. The chloroform solution was added to the PVA solution and continuously stirred (500 rpm) until the chloroform was completely evaporated.
- microspheres were washed sequentially with water, 0.1 iVHCI and water.
- the microspheres were graded and collected according to size on stainless steel sieves of 20 and 50 micrometer (20 micrometer sieve, S/Steel, NEN 2560, Endecotts, London; 50 micrometer sieve, S/Steel, ASIM E 11-87; B.V. metaalgaasweverij, Twente, The Netherlands) under sprinkled water, and dried under nitrogen.
- Non-irradiated 165 Ho-PLLA-MS show a smooth, spherical appearance.
- SEM surface electrospherical electrospherical electrospherical electrospherical electrospherical electrospherical electrospherical electrospherical electrospherical electrospherical electrospherical electrospherical electrospherical electrospherical electrospherical electrospherical electros.
- SEM small PLLA fragments.
- holmium loaded poly(L-lactic acid) microspheres also called herein "holmium microspheres”
- These microspheres can be used to generate an essentially non-radioactive diagnostic composition.
- the flowing behaviour of a particle of the invention, a site of angiogenesis, the presence of one or more tumours, and/or the distribution of said composition inside and around a tumour can for instance be determined. Additionally, it can be estimated whether significant shunting to the gastroduodenum and the lungs occurs.
- the invention thus provides a use of a particle of the invention for the preparation of a diagnostic composition.
- holmium loaded poly(L-lactic acid) microspheres can be rendered radioactive, for instance by neutron activation.
- These radioactive holmium microspheres can be used to generate a therapeutic composition.
- the distribution of said therapeutic composition inside said patient will be the same as the distribution of said diagnostic non- (or low-) radioactive composition, because said microspheres are chemically the same.
- the optimal amount of therapeutic composition can be determined.
- the administered essentially non-radioactive microsphere can be made radioactive in vivo. This can for instance be done by neutron activation.
- the administered amount of diagnostic composition appears not to be the optimal amount for the patient involved, since different patients can display different distribution patterns. Therefore, preferably an optimal amount of a radioactive therapeutic composition is administered after the distribution of said non-radioactive diagnostic composition is determined. It is also possible, in intervention MRI, to follow the administration and dosing of microspheres according to the present invention.
- an individual means an animal, preferably a human.
- a particle of the invention is meant herein a particle which is capable of at least in part disturbing a magnetic field, wherein said particle comprises a diameter of at least 1 ⁇ m.
- said particle is paramagnetic, for instance comprising holmium, gadolinium and/or dysprosium.
- a particle of the invention has a different susceptibility to a magnetic field as compared to the environment.
- a particle of the invention for instance comprises a molecule bound to an element capable of at least in part disturbing a magnetic field. Said molecule may form a cave wherein said element is present.
- said particle comprises a microsphere.
- any particle comprising said element falls within the scope of a particle of the invention.
- a particle only containing said element also falls within the scope of a particle of the invention.
- said element comprises holmium.
- a suspension of the invention is meant a suspension comprising a particle of the invention.
- composition or a particle which is more radioactive than another composition or particle is meant that the amount of radioactivity per mole is higher. This amount of radioactivity is normally expressed in becquerel.
- essentially non-radioactive is meant that the radioactivity is essentially the same as the normal background values generally present.
- chemically the same means that the chemical formula is essentially the same, or that a particle comprises an essentially similar shape while comprising essentially the same kind of sub-particle(s). Such sub-particle for instance comprises a particle of the invention.
- elements or compounds which are chemically the same may comprise different isotopes.
- a certain isotope of an element is considered to have essentially the same chemical properties compared to another isotope of the same compound.
- a particle with a diameter of 1 ⁇ m is meant that a batch of said particles comprises particles with a mean value of approximately 1 ⁇ m. For instance, if said batch comprises microspheres, the size of each individual microsphere can vary between approximately 0.5 and 2 ⁇ m.
- treating a tumour is meant herein that said tumour is counteracted. This can result in decreased growth of said tumour. In some cases growth can be stopped. Said tumour may be killed, although this is not necessarily the case.
- the invention further provides a method for treating an individual suffering from a tumour, comprising:
- a scanning suspension comprising a particle which is capable of at least in part disturbing a magnetic field
- Said particle in said therapeutic composition is more radioactive than said particle in said diagnostic composition, and/or is provided with at least one therapeutically active compound.
- said particle comprises holmium. More preferably, said particle comprises a diameter of at least 1 ⁇ m. Most preferably, the optimal amount of said therapeutic composition is derived from the distribution of said particle of said scanning suspension.
- said scanning suspension comprises a scanning suspension of the invention.
- a method of the invention is particularly suitable for treatment of a liver tumour, for instance a liver metastasis.
- Liver metastases frequently occur during the progression of various solid tumours, especially colorectal cancers, and are the cause of 25-50% of all cancer deaths.
- the median survival of patients with liver metastases ranges from 2-12 months depending on volume of the metastases and histology of the original tumour.
- Surgical resection is presently the only approach that offers patients with liver metastases substantial chance of cure. However this is an option for only 10-20 % of the patients.
- a particularly useful mode of therapy is the use of intra-arterially injected radioactive particles of the invention of a size sufficient to lodge in endarterioles.
- the basis for such therapy is that tumours are usually rich in vasculature and that liver metastases are almost exclusively dependent on arterial blood supply. This contrasts with normal liver, which receives most of its flow from the portal vein.
- This selectivity can also be increased by the use of vasoactive drugs, which cause vasoconstriction of the normal liver arterioles, but to which tumour vessels, lacking smooth muscle, are insensitive.
- other kind of tumours can also be treated by lodging of a blood vessel by a particle of the invention.
- the invention provides a use of a particle which is capable of at least in part disturbing a magnetic field as a medicament, wherein the dosage of said particle has been derived from a scanning image obtained with particles with essentially the same chemical structure.
- said medicament is capable of, at least in part, treating a tumour, more preferably a liver metastasis.
- a use of a particle which is capable of at least in part disturbing a magnetic field for the preparation of a medicament for the treatment of a tumour, wherein the dosage of said particle has been derived from a scanning image obtained with particles with essentially the same chemical structure, is therefore also herewith provided.
- said particle comprises a diameter of at least 1 ⁇ m, more preferably about 3-5 ⁇ m, enabling said particle to get stuck in a blood vessel.
- a method or use of the invention is preferably provided wherein said particle comprises a composition capable of essentially maintaining its structure during irradiation for at least 0.5 hour, preferably about 1 hour, with a neutron flux of 5xl0 13 cm -2 .s _1 .
- said particle comprises a microsphere, most preferably a poly(L-lactic acid) microsphere.
- said composition comprises holmium chemically bound to a compound capable of essentially maintaining its structure during irradiation for 1 hour with a neutron flux of 5xl0 13 cm -2 .s -1 .
- chemical linkage improves stability of said particle and at least partly avoids release of holmium from said particle.
- the invention furthermore provides a method for preparing a therapeutic composition for treatment of a tumour, comprising the steps of: - in a first step obtaining a scanning image, more specifically an MRI image of a person provided with a scanning suspension of the invention; in a second step preparing a therapeutic suspension for treatment of a tumour, using particles with essentially the same chemical structure as said particles in said scanning suspension, which particles are made more radioactive than said particles in said scanning suspension.
- an amount of particles is prepared prior to obtaining said scanning image, wherein a first part of said amount of particles is used for preparing said scanning suspension and a second part of said amount of particles is used for preparing said therapeutic suspension.
- a method for preparing a therapeutic composition is provided, wherein a dose of radiation for rendering said particles for use in said therapeutic suspension radioactive, and/or the amount of particles to be used in said therapeutic suspension, is at least partly based on said scanning image obtained.
- a method of the invention wherein said particle comprises a microsphere, for instance a poly(L-lactic acid) microsphere.
- said particle comprises holmium.
- neutron activated radioactive holmium loaded poly(L-lactic acid) microspheres (Ho-PLLA-MS) emit gamma rays which can be used for imaging with a gamma-camera and beta particles for treatment of a patient. Animal studies showed that these microspheres can be targeted to the tumour and that they can be easily imaged with a gamma camera. Since holmium is paramagnetic it can also be viewed by non-radioactive scanning methods such as MRI. It is therefore possible to image non-radioactive holmium loaded microspheres.
- Imaging of non-radioactive holmium loaded microspheres before treatment with radioactive microspheres results in a radiation reduction for the patient and medical personnel. In that case no special precautionary measures have to be taken against (too much) exposure to ionizing radiation, as has been explained above. Moreover, more time is now available for determining a distribution pattern. Said distribution can now be determined during the whole time that said particles are present within an individual, whereas a radioactive tracer dose should be detected before radioactivity has decayed.
- holmium loaded microspheres can be also followed over time.
- the invention provides a method for obtaining a scanning image, comprising administering a scanning suspension to an individual and subsequently generating a scanning image of said individual, wherein said scanning suspension comprises a scanning suspension of the invention.
- the purpose of this study was to investigate the possibility of measuring the biodistribution of holmium loaded microspheres with MRI. Measurements were done in phantoms, in ex- vivo rabbit livers and in rabbits. MR images of the rabbits were compared with gamma scintigraphic images.
- Radioactive holmium loaded microspheres were prepared as previously described [14]. Briefly, holmium acetylacetonate [20] is incorporated into poly(L-lactic acid) by solvent evaporation, resulting in microspheres of 20-50 ⁇ m after sieving. Neutron activation of the microspheres was performed by irradiation for lh in the PRS facility of the high-flux nuclear reactor in Petten, The Netherlands. Prior to administration during the in- vivo and ex-vivo experiments the microspheres were sonicated for 10 min in an ultrasonic cleaner and suspended in Gelofusine® (Vifor Medical SA, Switzerland).
- Phantoms For preparation of the agar gel matrix dry agar powder (20g; Life technologies GIBCO BRL, Paisley, Scotland) was mixed in cold deionized water (lOOOg) with manganese(II) chloride tetrahydrate (900 mg; Merck, Darmstadt, Germany). The manganese-chloride was used to simulate liver NMR properties. Holmium or yttrium loaded poly(L-lactic acid) microspheres (Ho-PLLA-MS or Y-PLLA-MS) were suspended in the agar solution under stirring. The microspheres suspension and agar suspension were heated till 100 °C for 10 minutes resulting in transparent fluid gels.
- Ho-PLLA-MS or Y-PLLA-MS Holmium or yttrium loaded poly(L-lactic acid) microspheres
- the gels were added in different proportions to each other which resulted in a rising Ho-PLLA-MS and Y-PLLA-MS concentration.
- the mixed gels were sonicated during cooling. Once cooled to room temperature, the gel is optically transparent with visible homogeneously distributed microspheres.
- a tube with an inner diameter of 12 mm was chosen as a scaled model of the human inferior vena cava, which has a diameter of around 24 mm.
- the tube was placed in a Plexiglas container, filled with manganese-doped water as a background, mimicking muscle tissue.
- An air-pressure-driven flow pump generating a constant flow of 17 ml s was connected to the phantom, yielding a flow velocity of 15 cm/s, which is a velocity expected for an average human vena cava.
- the circulating and background fluid consisted of water with manganese-chloride (19.2 mg/1 MnCl2.4H 2 0).
- the manganese solution was used to approximate the relaxation times of human blood.
- a holmium-sensitive dynamic sequence (as described in the MR imaging section) was used. After acquisition of a base-line value, a short injection of microspheres was given via a 5F injection catheter, and this was subsequently flushed with approximately 4 ml of the blood mimicking fluid.
- the injected doses of microspheres ranged from 4.4 to 31 mg.
- the shunting experiment was also carried out for larger and slowly injected doses (respectively 40, 48 and 53 mg).
- Analgesia, sedation and euthanasia Analgesia, sedation and euthanasia. Analgesia and sedation during laparatomies were achieved with 0.5 ml methadone (lOmg/ml; Veterinary Pharmacy, University of Utrecht, The Netherlands) and 0.5 ml Ventranquil ® (acepromazine, 10 mg/ml; Sanofi Sante Animale Benelux BV, Maassluis, The Netherlands). Subsequently, the rabbits were anaesthetized by an intravenous injection of Hypnomidate ® (2mg/ml; B.
- VX2 cell line [21] was obtained from the Department of Oral and Maxillofacial Surgery of the University Medical Center, Utrecht, The
- VX2 tumour was propagated by subcutaneous passage in the hip region of the rabbit. After the tumour was dissected small parts (2 mm in diameter) were chosen for implantation.
- Tumour implantation Tumour parts (two or three) were injected in the left lateral lobe with an Abbocath ® 18G (Abbocath Ltd., Ireland). The injection wound was sealed with tissue glue (Histoacryl, B. Braun Melsungen AG, Melsungen, Germany). After approximately 12 days the first ultrasound investigation (HDI 3000 ATL, EntosTM CL10-5 transducer) was performed to check tumour growth.
- the gastroduodenal artery was cannulated with an Abbocath ® 24G (Abbott Ltd., Ireland). Back flow was checked with 0.1% methylene blue in 5% glucose.
- a pre-flushed administration system similar as described by Herba et al. [23] was connected to the Abbocath ® .
- the suspended microspheres were administered and the syringe was measured for activity pre- and post injection, in order to calculate the injected dosage.
- the gastroduodenal artery was ligated or if possible sealed with tissue glue
- MR images were taken before, three days after and 17 days after administration of the radioactive microspheres.
- SPECT images were taken three days after administration. In order to verify presence of microspheres liver was embedded in paraffin and histolo ically evaluated after staining with haematoxylin- eosin.
- liver was derived from a rabbit used in a terminal animal experiment. No extra rabbits were killed for performing these ex-vivo experiments. A needle was jabbed in the left ventricle of the heart and the right auricle was cut away. The rabbit was flushed with saline and heparine;
- liver was flushed with saline and heparine via the hepatic artery.
- the livers were stored in saline by 5 °C during a maximum of 30 hours.
- the suspended microspheres were administered via the hepatic artery during the dynamic MR-imaging experiments.
- SE multi-echo spin echo
- a dynamic transversal T2*-weighted FFE (resolution 2 mm, slice 30 mm, echo-time (TE) 15 ms, 0.352 s/dynamic) was performed.
- the increase of transversal relaxation rate ( ⁇ R2*) due to passing microspheres was calculated by means of observed signal change, relative to an acquired base-line value.
- the imaging protocol for both ex vivo and in vivo MR measurements before and after administration of the holmium-loaded microspheres included anatomical Tl-weighted SE (TE 9.5 ms) imaging, tumour sensitive T2- weighted SE imaging (TE 90 ms) and holmium-sensitive T2*-weighted FFE imaging (TE 4.6, 9.2 ms).
- TE 9.5 ms anatomical Tl-weighted SE
- tumour sensitive T2- weighted SE imaging TE 90 ms
- holmium-sensitive T2*-weighted FFE imaging TE 4.6, 9.2 ms.
- a dynamic T2*- weighted FFE (resolution 2 mm, TE 9.2 ms, slice thickness 4 or 10 mm, 1 s per slice) sequence was also used to depict the administration of the microspheres.
- Microspheres prepared by solvent evaporation resulted after sieving in 3-5 grams spherical particles with a diameter of 20-50 ⁇ m (Fig. 1) and a holmium content of 15-17% (w/w).
- Phantoms Rl and R2 as measured by the multi spin-echo with inversion recovery experiment were largely independent of the concentration of holmium microspheres, Figure 2.
- Figure 3 shows the R 2 * dependence on HoMS concentration.
- the transverse relaxivity corresponds to that predicted for the static dephasing regime [25], where the susceptibility of the HoMS is calculated using the Curie law from the magnetic moment of uncoupled Ho ions (10.4 Bohr magnetons) and the Ho content of the microspheres.
- Detection of passing holmium-loaded microspheres in order to estimate lung shunting in a scaled model of an average human vena cava showed the ability of dynamic MRI to detect all injected single doses (Table 1), which is illustrated in Figure 9 for a dose of 6.7 mg and 48 mg. The latter dose was injected slowly to simulate shunting of microspheres over time. This figure shows that after acquisition of a base-line value, a dose of a few mg is easily detected. For all other injected doses, measured changes in relaxation rates were linearly proportional to the amount of administrated microspheres.
- MRI of the rabbit before administration of holmium loaded microspheres resulted in an ideal diagnostic tool for the visuahsation of the VX2-tumours (Fig. 6a).
- the tumours appear as an homogeneous, round sharply marginated lesion.
- On Tl-weighted images the tumours are hypointense and on T2- weighted images they appear as hyperintense lesions compared with hver tissue.
- field disturbances were seen in the tumour and in the liver caused by accumulation of holmium loaded microspheres (Fig. 6b-c).
- the T2-weighted image is more sensitive for holmium as is shown by the increased black areas in the liver and especially around the tumour. No holmium accumulation was seen in the nucleus of the tumour (Fig.6d).
- Phantom experiments with holmium loaded poly(L-lactic acid) microspheres suspended in agar show a susceptibihty of the HoMS which can be described by the Curie law, indicating no magnetic interactions between the Ho-ions.
- the magnetic susceptibility for Ho is comparable of that of Dy [17].
- MR imaging is very useful to identify the anatomical structure of the abdominal region.
- the tumour is visible as a spherical tissue mass in the left lateral lobe. Sizes of the tumour measured with echo and with a ruler are comparable to the measurements with MRI. After administration of the radioactive holmium loaded microspheres accumulation was seen in and especially around the tumour. This can be explained by the tumour angiogenesis of liver metastases.
- Liver tumours have often a hypervascular brim and derive their blood supply almost exclusively from the hepatic artery [32]. Microspheres injected into the hepatic artery therefore accumulate around the tumour. On both scintigraphic and MR images an inhomogeneous distribution of the holmium microspheres in the liver was observed. This heterogeneous distribution is described also for human patients and can explain the toleration of the liver for high doses of activity [32; 33]. Large parts of the liver will receive less activity than would be expected for a uniform distribution of activity resulting in survival of most of the liver tissue. MR and scintigraphic images show both the holmium accumulation in the animal.
- Tumour to liver ratio is to be understood as the ratio between the activity of and/or the number of particles in the tumour relative to the activity of and/or the number of particles in the liver. A higher ratio is therefore more effective.
- Growthmium microspheres can be imaged after treatment as long as they accumulate in the body. Information about redistribution and tissue reaction on such particles can be observed with MR. The animal experiments in rabbits show that redistribution is not seen during the first 17 days.
- Figure la-b a) Scanning electron micrograph of holmium loaded PLLA microspheres. b) Volume weight distribution of sieved microspheres. The used microspheres for the experiments had a mean diameter of 30 ⁇ m and 96% of the volume of the particles had a diameter between 20 and 40 ⁇ m.
- Figure 2a-b a) Ri and b) R2 versus HoMS concentration.
- the solid line is a least squares fit to the data points.
- Fig.4a-b a) Picture of the tumour on the left lateral liver lobe, b) Liver overview of the rabbit.
- the tumour is implanted 10 mm from the brim of the lobe (white dot).
- This liver lobe which is laying on the stomach can be easily attained for implantation.
- Left medial lobe (II) and right medial lobe (III) are partly fused to each other and are laying on the stomach.
- the gall bladder is positioned on the back of the right medial lobe.
- the right lateral lobe (IV) is laying next to the stomach close to the backbone which is also seen on figure 6.
- the larger arrow indicates the microspheres in and around the tumour
- the small scintigraphic image in the right upper corner shows the contours of the rabbit obtained by using a "flood source”. Contour of the rabbit was obtained using the "flood source”.
- Increased accumulation of radioactivity ⁇ thus holmium loaded microspheres ⁇ is indicated with small arrows.
- the larger arrow indicates the activity in and around the tumour.
- FIG. 6a-d Magnetic resonance images of the transverse plane of the rabbit
- b) Schematic drawing shows the organs which are seen in the images. The colour and position of the organs corresponds with the small drawings in each MRI image
- d) T2-weighted FFE (TE 4.6 and 9.2 msec) image after administration of the microspheres.
- FIG. 7a-c Magnetic resonance images of the tumour bearing rabbit liver 4 weeks after treatment, a) Tl-weighted SE image, b) T2-weighted FFE image with field disturbances caused by holmium accumulation. White arrow indicate the tumour side, c) Ex-vivo liver with tumour (black arrow). The right lateral lobe is increased while the other lobes and the tumour are growth to each other.
- Figure 8a-c Dynamic magnetic resonance images (c) of the administration of holmium loaded microspheres in an ex-vivo liver (without tumour) of a rabbit (a-b). The administration was mainly selective for the medial lobes.
- Figure 9 Detection of holmium-loaded microspheres passing a scaled model of a human vena cava. Dashed lines denote the base Une values before injection of the boluses. For the small dose (5.5 mg), a rapid injection was given at point A, whereas the large dose was injected from points B to C. Point D is a rapid flushing of the injection catheter with the circulating fluid. The areas between the base-lines and the curves are proportional to the injected doses, a.u.: arbitrary units.
- VX2 carcinoma in the rabbit auricle as an experimental model for intra-arterial embolization of head and neck squamous cell carcinoma with dextran microspheres. Lab Anim 1999; 33(2): 175-184.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES03741661T ES2396911T3 (en) | 2002-07-02 | 2003-07-02 | Scanning suspension comprising a particle whose diameter reaches at least 1 micrometer |
CA2491484A CA2491484C (en) | 2002-07-02 | 2003-07-02 | Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
AU2003281270A AU2003281270B2 (en) | 2002-07-02 | 2003-07-02 | Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
EP03741661A EP1519757B1 (en) | 2002-07-02 | 2003-07-02 | Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
JP2004519358A JP2005531643A (en) | 2002-07-02 | 2003-07-02 | Scanning suspension comprising particles having a diameter of at least 1 micrometer |
US11/025,360 US8632751B2 (en) | 2002-07-02 | 2004-12-29 | Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
US14/108,567 US9731037B2 (en) | 2002-07-02 | 2013-12-17 | Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02077626.6 | 2002-07-02 | ||
EP02077626 | 2002-07-02 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/025,360 Continuation US8632751B2 (en) | 2002-07-02 | 2004-12-29 | Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
US11/025,360 Continuation-In-Part US8632751B2 (en) | 2002-07-02 | 2004-12-29 | Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004004786A1 true WO2004004786A1 (en) | 2004-01-15 |
Family
ID=30011146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2003/000485 WO2004004786A1 (en) | 2002-07-02 | 2003-07-02 | Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
Country Status (7)
Country | Link |
---|---|
US (2) | US8632751B2 (en) |
EP (1) | EP1519757B1 (en) |
JP (2) | JP2005531643A (en) |
AU (1) | AU2003281270B2 (en) |
CA (1) | CA2491484C (en) |
ES (1) | ES2396911T3 (en) |
WO (1) | WO2004004786A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009505709A (en) * | 2005-08-25 | 2009-02-12 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Image-based planning method and apparatus for targeted therapy |
US8632751B2 (en) | 2002-07-02 | 2014-01-21 | Universitair Medisch Centrum Utrecht | Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210299056A9 (en) * | 2004-10-25 | 2021-09-30 | Varian Medical Systems, Inc. | Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods |
WO2017059269A1 (en) | 2015-10-02 | 2017-04-06 | Southern Research Institute | Imaging phantom and systems and methods of using same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863715A (en) * | 1984-03-29 | 1989-09-05 | Nycomed As | Method of NMK imaging using a contrast agent comprising particles of a ferromagnetic material |
US4985233A (en) * | 1984-11-01 | 1991-01-15 | Nycomed /As | A diagnostic agent containing a non-radioactive paramagnetic metal species in a macromolecular carrier |
WO1992017214A2 (en) * | 1991-04-04 | 1992-10-15 | Ranney David F | Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement |
WO1993010440A1 (en) * | 1991-11-19 | 1993-05-27 | Unger Evan C | Gel particle contrast media for improved diagnostic imaging |
US5512268A (en) * | 1993-03-26 | 1996-04-30 | Vivorx Pharmaceuticals, Inc. | Polymeric shells for medical imaging prepared from synthetic polymers, and methods for the use thereof |
DE19958586A1 (en) * | 1999-12-06 | 2001-06-07 | Aventis Res & Tech Gmbh & Co | Microparticles based on aspartic acid and their use as MRI contrast agents |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5976A (en) * | 1982-06-22 | 1984-01-05 | 日本電気株式会社 | High energy ct for radiation treatment |
US5099505A (en) | 1990-07-02 | 1992-03-24 | Varian Associates | Method for increasing the accuracy of a radiation therapy apparatus |
JPH0812598A (en) * | 1994-06-30 | 1996-01-16 | Daiichi Rajio Isotope Kenkyusho:Kk | Therapuetic agent for tumor |
WO1997001304A1 (en) * | 1995-06-29 | 1997-01-16 | Mallinckrodt Medical, Inc. | Radiolabeled apatite particles containing a paramagnetic ion |
NL1006135C2 (en) * | 1997-05-27 | 1998-12-01 | Academisch Ziekenhuis Utrecht | Apparatus and method for preparing radioactive drugs for administration. |
JPH10328319A (en) | 1997-05-29 | 1998-12-15 | Hitachi Medical Corp | Radiotherapy system |
JP4733809B2 (en) | 2000-05-23 | 2011-07-27 | 株式会社東芝 | Radiation therapy planning device |
EP1519757B1 (en) | 2002-07-02 | 2012-09-19 | Universitair Medisch Centrum Utrecht | Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
US7572448B2 (en) * | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
EP2017253A1 (en) * | 2007-07-19 | 2009-01-21 | UMC Utrecht Holding B.V. | A particle comprising an organic lanthanide metal complex |
EP2457588A1 (en) * | 2010-11-05 | 2012-05-30 | UMC Utrecht Holding B.V. | Microsphere comprising a lanthanide metal complex |
-
2003
- 2003-07-02 EP EP03741661A patent/EP1519757B1/en not_active Expired - Lifetime
- 2003-07-02 AU AU2003281270A patent/AU2003281270B2/en not_active Expired
- 2003-07-02 WO PCT/NL2003/000485 patent/WO2004004786A1/en active Application Filing
- 2003-07-02 ES ES03741661T patent/ES2396911T3/en not_active Expired - Lifetime
- 2003-07-02 JP JP2004519358A patent/JP2005531643A/en active Pending
- 2003-07-02 CA CA2491484A patent/CA2491484C/en not_active Expired - Lifetime
-
2004
- 2004-12-29 US US11/025,360 patent/US8632751B2/en active Active
-
2010
- 2010-11-30 JP JP2010267300A patent/JP2011068667A/en active Pending
-
2013
- 2013-12-17 US US14/108,567 patent/US9731037B2/en not_active Expired - Lifetime
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863715A (en) * | 1984-03-29 | 1989-09-05 | Nycomed As | Method of NMK imaging using a contrast agent comprising particles of a ferromagnetic material |
US4985233A (en) * | 1984-11-01 | 1991-01-15 | Nycomed /As | A diagnostic agent containing a non-radioactive paramagnetic metal species in a macromolecular carrier |
US5213788A (en) * | 1988-09-29 | 1993-05-25 | Ranney David F | Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement |
WO1992017214A2 (en) * | 1991-04-04 | 1992-10-15 | Ranney David F | Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement |
WO1993010440A1 (en) * | 1991-11-19 | 1993-05-27 | Unger Evan C | Gel particle contrast media for improved diagnostic imaging |
US5512268A (en) * | 1993-03-26 | 1996-04-30 | Vivorx Pharmaceuticals, Inc. | Polymeric shells for medical imaging prepared from synthetic polymers, and methods for the use thereof |
DE19958586A1 (en) * | 1999-12-06 | 2001-06-07 | Aventis Res & Tech Gmbh & Co | Microparticles based on aspartic acid and their use as MRI contrast agents |
Non-Patent Citations (2)
Title |
---|
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1996, WEBB ET AL.: "Sonochemically produced fluorocarbon microspheres: a new class of magnetic resonance imaging agent", XP002231065, retrieved from MEDLINE Database accession no. nlm8835962 * |
WEBB ET AL.: "Sonochemically produced fluorocarbon microspheres: a new class of magnetic resonance imaging agent", JOURNAL OF MAGNETIC RESONANCE IMAGING, vol. 6, no. 4, 1996, pages 675 - 683 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8632751B2 (en) | 2002-07-02 | 2014-01-21 | Universitair Medisch Centrum Utrecht | Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
US9731037B2 (en) | 2002-07-02 | 2017-08-15 | Universitair Medisch Centrum Utrecht | Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
JP2009505709A (en) * | 2005-08-25 | 2009-02-12 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Image-based planning method and apparatus for targeted therapy |
Also Published As
Publication number | Publication date |
---|---|
US8632751B2 (en) | 2014-01-21 |
US9731037B2 (en) | 2017-08-15 |
AU2003281270B2 (en) | 2010-07-22 |
EP1519757A1 (en) | 2005-04-06 |
US20140227177A1 (en) | 2014-08-14 |
ES2396911T3 (en) | 2013-03-01 |
US20050201940A1 (en) | 2005-09-15 |
JP2005531643A (en) | 2005-10-20 |
EP1519757B1 (en) | 2012-09-19 |
CA2491484C (en) | 2013-06-11 |
JP2011068667A (en) | 2011-04-07 |
CA2491484A1 (en) | 2004-01-15 |
AU2003281270A1 (en) | 2004-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nijsen et al. | Liver tumors: MR imaging of radioactive holmium microspheres—phantom and rabbit study | |
Anzai et al. | Iron oxide‐enhanced MR lymphography: the evaluation of cervical lymph node metastases in head and neck cancer | |
Lee et al. | Distribution of iron oxide–containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy | |
JP6174603B2 (en) | Contrast agent for T2 * -weighted magnetic resonance imaging (MRI) | |
US20060204443A1 (en) | Methods for tumor treatment using dendrimer conjugates | |
JPH07110815B2 (en) | Polychelating agent for image and spectral enhancement (and spectral shift) | |
JPS61501633A (en) | contrast agent | |
US20090317327A1 (en) | Aqueous Dispersion of Superparamagnetic Single-Domain Particles, Production and Use Thereof in Diagnosis and Therapy | |
Shanehsazzadeh et al. | Biodistribution of ultra small superparamagnetic iron oxide nanoparticles in BALB mice | |
US9731037B2 (en) | Scanning suspension comprising a particle with a diameter of at least 1 micrometer | |
Song et al. | Rat model of metastatic breast cancer monitored by MRI at 3 tesla and bioluminescence imaging with histological correlation | |
JP4965020B2 (en) | Contrast-enhanced magnetic resonance imaging of tissue perfusion | |
US7247501B2 (en) | Imaging and targeting tumors using sickle cells | |
WO2022041803A1 (en) | Visualized radioactive carbon microsphere, and preparation method and application thereof | |
JP2020504106A (en) | Radiolabeled substances for targeted administration | |
Zielhuis et al. | Characterization of holmium loaded alginate microspheres for multimodality imaging and therapeutic applications | |
Sinha et al. | Diagnostic microspheres: an overview | |
CA3198991A1 (en) | Radiolabeled liposomes and methods of use thereof | |
Ghorbani et al. | Magnetic particle imaging and its application | |
Brown et al. | Sickle red blood cells accumulate in tumor | |
Suto et al. | Dual contrast magnetic resonance imaging with combined use of positive and negative contrast agent in human hepatocellular carcinoma | |
Thakur et al. | MR imaging of pulmonary parenchyma and emboli by paramagnetic and superparamagnetic contrast agents | |
Weber et al. | Imaging in oncology research | |
Landini et al. | Fundamentals in cardiovascular imaging technologies | |
Vincenti et al. | Increased Sensitivity of Computed Tomography Scan for Neoplastic Tissues Using the Extracellular Vesicle Formulation of the Contrast Agent Iohexol. Pharmaceutics 2022, 14, 2766 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11025360 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2491484 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004519358 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003281270 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003741661 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003741661 Country of ref document: EP |